Rhenman & Partners Asset Management AB Sells 133,288 Shares of Viking Therapeutics, Inc. $VKTX

Posted by Geri Gentry on Jun 13th, 2026

Rhenman & Partners Asset Management AB decreased its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 61.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 83,000 shares of the biotechnology company’s stock after selling 133,288 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Viking Therapeutics were worth $2,920,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Raleigh Capital Management Inc. increased its holdings in shares of Viking Therapeutics by 58.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 945 shares of the biotechnology company’s stock worth $33,000 after buying an additional 347 shares during the last quarter. Fifth Third Bancorp increased its holdings in shares of Viking Therapeutics by 169.3% in the 4th quarter. Fifth Third Bancorp now owns 1,077 shares of the biotechnology company’s stock worth $38,000 after buying an additional 677 shares during the last quarter. Lodestone Wealth Management LLC bought a new position in shares of Viking Therapeutics in the 4th quarter worth $39,000. GAMMA Investing LLC increased its holdings in shares of Viking Therapeutics by 71.0% in the 4th quarter. GAMMA Investing LLC now owns 1,195 shares of the biotechnology company’s stock worth $42,000 after buying an additional 496 shares during the last quarter. Finally, TD Waterhouse Canada Inc. increased its holdings in shares of Viking Therapeutics by 250.0% in the 4th quarter. TD Waterhouse Canada Inc. now owns 1,400 shares of the biotechnology company’s stock worth $49,000 after buying an additional 1,000 shares during the last quarter. Institutional investors own 76.03% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. BTIG Research reissued a “buy” rating and issued a $125.00 price target on shares of Viking Therapeutics in a report on Friday, May 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viking Therapeutics in a research note on Monday, April 20th. Truist Financial initiated coverage on shares of Viking Therapeutics in a research note on Wednesday, May 27th. They issued a “buy” rating and a $83.00 price objective for the company. Zacks Research raised shares of Viking Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 18th. Finally, Cantor Fitzgerald cut their price objective on shares of Viking Therapeutics from $105.00 to $100.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $93.60.

View Our Latest Stock Report on VKTX

Viking Therapeutics Stock Performance

Shares of Viking Therapeutics stock opened at $28.75 on Friday. Viking Therapeutics, Inc. has a 52-week low of $22.96 and a 52-week high of $43.15. The stock has a market capitalization of $3.34 billion, a price-to-earnings ratio of -6.94 and a beta of 0.69. The company has a fifty day moving average of $31.90 and a 200-day moving average of $32.87.

Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.36). During the same quarter in the prior year, the firm earned ($0.41) EPS. On average, equities research analysts forecast that Viking Therapeutics, Inc. will post -4.7 earnings per share for the current fiscal year.

Viking Therapeutics Profile

(Free Report)

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.